Blood Res.  2022 Sep;57(3):239-241. 10.5045/br.2022.2022105.

Low-level somatic JAK2 V617F mutation in myelodysplastic/ myeloproliferative neoplasm with ring sideroblasts, and thrombocytosis with co-mutated SF3B1 and CALR

• Ji YS
• Park SK
• Jeon BR
• Jang MA

• KMID: 2533253
• DOI: http://doi.org/10.5045/br.2022.2022105

Figure

• 

  Fig. 1 Hematological and molecular characteristics of the present MDS/MPN-RS-T patient with triple SF3B1, CALR, and JAK2 driver mutations. (A) Wright–Giemsa stain (×400) of bone marrow aspirate showing dyserythropoiesis with multinuclearity and megaloblastoid changes (arrows). (B) Iron stain (×1,000) showing ring sideroblasts (arrows). (C) Wright–Giemsa stain (×200) showing increased cellularity and proliferation of large pleomorphic megakaryocytes. (D–F) Integrative Genomics Viewer snapshot of SF3B1 missense mutation (NC_000002.11:g.198267483C>T, R625H) (D), CALR frameshift mutation (NC_000019.9:g.13054590del, D373TfsTer57) (E), and JAK2 missense mutation (NC_000009.11: g.5073770G>T, V617F) (F) identified by next-generation sequencing (arrowheads).

Reference

1. Patnaik MM, Tefferi A. 2021; Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management". Am J Hematol. 96:379–94. DOI: 10.1002/ajh.26090. PMID: 33428785.

2. Patnaik MM, Lasho TL. 2020; Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. Hematology Am Soc Hematol Educ Program. 2020:450–9. DOI: 10.1182/hematology.2020000130. PMID: 33275756. PMCID: PMC7727543.

3. Swerdlow SH, Campo E, Harris NL, et al. 2017. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. IARC Press;Lyon, France: p. 93–4.

4. Thorvaldsdóttir H, Robinson JT, Mesirov JP. 2013; Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 14:178–92. DOI: 10.1093/bib/bbs017. PMID: 22517427. PMCID: PMC3603213.

5. Yasuda H, Morishita S, Mori Y, et al. 2021; JAK2/CALR/SF3B1 triple-mutated myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis evolving to myelofibrosis and SF3B1 single-mutated acute myeloid leukemia: evidence of a pre-JAK2 clone. Leuk Res. 100:106496. DOI: 10.1016/j.leukres.2020.106496. PMID: 33373831.

6. Ye MT, Wang Y, Wang SA, et al. 2020; Concurrent JAK2 V617F and MPL W515L in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leuk Lymphoma. 61:963–6. DOI: 10.1080/10428194.2019.1691202. PMID: 31750750.

7. Nielsen C, Bojesen SE, Nordestgaard BG, Kofoed KF, Birgens HS. 2014; JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate. Haematologica. 99:1448–55. DOI: 10.3324/haematol.2014.107631. PMID: 24907356. PMCID: PMC4562533.

8. Stead LF, Sutton KM, Taylor GR, Quirke P, Rabbitts P. 2013; Accurately identifying low-allelic fraction variants in single samples with next-generation sequencing: applications in tumor subclone resolution. Hum Mutat. 34:1432–8. DOI: 10.1002/humu.22365. PMID: 23766071.